EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound (HIFU) for the Treatment of Rectal Endometriosis
EDAP TMS announced positive results from the Endo-HIFU-R1 Phase 2 study, focused on the safety of Focal One® HIFU treatment for rectal endometriosis. Presenting at the Paris Santé Femmes Congress on January 27, the study revealed a 96.7% safety profile with non-significant adverse events. Enrolling 60 patients, the study demonstrated a marked improvement in endometriosis symptoms and quality of life over six months post-treatment. Following these results, EDAP plans to start a randomized, double-blind, SHAM-controlled study in Q2 2023 to confirm efficacy. This milestone showcases the potential of HIFU as a non-invasive alternative to traditional surgery.
- 96.7% of patients experienced no or non-significant adverse events.
- Significant long-term improvement in endometriosis symptoms and quality of life after treatment.
- Plans to initiate a randomized efficacy study in Q2 2023.
- None.
Focal One® HIFU treatment resulted in significant improvements in endometriosis symptoms and quality of life (QoL)
Positive safety profile with 96.7% of patients with no or non-significant adverse events
Data was presented at the Paris Santé Femmes Major Gynecology French Congress on Friday, January 27
Company intends to initiate randomized, double-blind, SHAM-controlled study in 2Q 2023
LYON, France, January 31, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced positive clinical results from the Endo-HIFU-R1 Phase 2 study evaluating the safety of therapeutic high-Intensity focused ultrasound (HIFU) for the treatment of rectal endometriosis. Results from the study were presented by study coordinator, Pr. Gil Dubernard of Croix Rousse University Hospital (Lyon, France), on Friday, January 27, at the Paris Santé Femmes French Congress1 (Lille, France).
Endo-HIFU-R1 is a Phase 2 study designed to evaluate the safety of HIFU treatment of rectal endometriosis with EDAP’s Focal One® Robotic HIFU device. The study enrolled 60 patients across four centers in France between August 2020 and March 2022. Results from the study are based upon a six-month follow-up evaluation post-HIFU treatment.
“These encouraging results validate the safety of Focal One HIFU treatment in this difficult and challenging endometriosis population,” said Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS. “Positive data from the Endo-HIFU-R1 study represent an important milestone for EDAP and also underscore the potential of Focal One Robotic HIFU as a promising new treatment modality for patients suffering from this debilitating pathology. We would like to thank all of the patients and clinical investigators who participated in this important study. Based on these results, EDAP TMS intends to confirm the efficacy of Focal One HIFU treatment in rectal endometriosis by initiating a randomized, double-blind controlled study in the second quarter of 2023.”
“Surgery is typically done to excise or ablate the lesions and surrounding fibrotic tissue in patients with significant rectal endometriosis, which is often associated with post-surgical morbidities, including up to
Endo-HIFU-1R Study Results
Treatment with Focal One HIFU showed a positive safety profile with
With respect to QoL measurement, a significant improvement was also observed from the first month after HIFU treatment and maintained at three and six months after treatment for almost all evaluated criteria: physical functioning, role limitation due to emotional problems, energy – fatigue, emotional well-being, social functioning, bodily pain, general health, and on physical and mental global score components.
The study also blindly evaluated the evolution of nodule volume via MRI, and a significant reduction of the volume of lesions was observed at six months.
About Endometriosis
Endometriosis is a chronic, progressive disease affecting nearly 10
1 Paris Santé Femmes is a National Event gathering experts and obstetric surgeons community in France (https://paris-sante-femmes.fr/).
2 Source: https://drseckin.com/rectal-endometriosis/
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
FAQ
What were the results of the Endo-HIFU-R1 Phase 2 study for EDAP (EDAP)?
When were the results of the EDAP Endo-HIFU-R1 study presented?
What is the next step for EDAP following the Endo-HIFU-R1 study results?
How many patients were enrolled in the Endo-HIFU-R1 study?